Teva Pharma Files DEF 14A on Executive Compensation
Ticker: TEVJF · Form: DEF 14A · Filed: Apr 9, 2025 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | DEF 14A |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Teva's 2025 DEF 14A is out, detailing exec pay & stock awards for 2024. Watch for equity vesting details.
AI Summary
Teva Pharmaceutical Industries Ltd. filed its DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, vested, and forfeited for executives such as Kare Schultz and Richard Francis, with details on fair value changes and performance-based awards.
Why It Matters
This filing provides transparency into how Teva Pharmaceutical Industries compensates its top executives, offering insights into the company's performance-based incentives and potential future stock dilution.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal significant details about executive compensation, stock awards, and potential future dilution, which can impact investor sentiment and stock price.
Key Numbers
- 2024 — Fiscal Year End (Executive compensation details pertain to this year.)
- 20250409 — Filing Date (The date Teva Pharmaceutical Industries Ltd. filed this DEF 14A.)
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Filer
- Kare Schultz (person) — Executive
- Richard Francis (person) — Executive
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information on matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
Who are the key executives mentioned in relation to equity awards?
The filing mentions Kare Schultz and Richard Francis in relation to equity awards for the fiscal years 2020 through 2024.
What specific types of equity awards are detailed in the filing?
The filing details equity awards such as 'DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYr', 'FairValueAtLastDayOfPriorYearOfEquityAwardsForfeitedDuringYear', and 'ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr'.
What is the fiscal year end for Teva Pharmaceutical Industries Ltd. as indicated in the filing?
The fiscal year end for Teva Pharmaceutical Industries Ltd. is December 31st (1231).
When is the company's next shareholder meeting or vote expected, based on the filing date?
The filing is dated April 9, 2025, and is the 'CONFORMED PERIOD OF REPORT' for June 5, 2025, suggesting that shareholder matters related to this period would be addressed around that time.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 9, 2025 by Kare Schultz regarding TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF).